<DOC>
	<DOCNO>NCT00698516</DOCNO>
	<brief_summary>Combination Hycamtin ( topotecan ) Avastin ( bevacizumab ) could allow kill endothelial neoplastic cell . We postulate addition bevacizumab topotecan increase delivery topotecan tumor cell may enhance activity topotecan patient previously treat small cell lung cancer improve progression free survival .</brief_summary>
	<brief_title>Study Oral Topotecan With Bevacizumab Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis SCLC . First recurrence SCLC therapy one prior chemotherapy regimen initial diagnosis . Relapsed SCLC duration ( sensitive resistant relapse ) . ECOG performance status &lt; /= 2 . Adequate bone marrow reserve , hepatic , renal , cardiovascular function . No prior therapy bevacizumab VEGF inhibitor topotecan Uncontrolled emesis , regardless etiology . Active uncontrolled infection . GI condition drug could impact absorption oral topotecan . Known hypersensitivity component topotecan capsule compound chemically related topotecan . Uncontrolled hypertension BP &gt; 150/100 . Prior h/o hypertensive crisis encephalopathy . NYHA Grade II great congestive heart failure . H/O myocardial infarction within 6 month . H/O stroke TIA within 6 month . H/O thrombotic hemorrhagic disorder . Clinically significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month . Major surgical procedure , open biopsy , significant traumatic injury within 28 day . Anticipation need major surgical procedure study . Minor surgical procedure within 7 day prior treatment start ( placement vascular access device permit ) . H/O abdominal fistula , GI perforation , intraabdominal abscess within prior 6 month . Serious , nonhealing wound , active ulcer , untreated bone fracture . H/O hemoptysis within prior 1 month . Concurrent radiotherapy . H/O whole lung radiation within 90 day prior start treatment . Presence h/o central nervous system brain metastasis . H/o another malignancy SCLC . Concurrent chemotherapy , immunotherapy , investigational therapy treatment small cell lung cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Small Cell Lung Cancer ( SCLC )</keyword>
	<keyword>Topotecan</keyword>
</DOC>